November 13, 2013
Sunovion Pharmaceuticals Inc., a US subsidiary of Dainippon Sumitomo Pharma (DSP), said on November 8 that its antiepileptic drug Aptiom (eslicarbazepine acetate) has won US regulatory approval for use as an adjunctive treatment for partial-onset seizures in adults aged 18...read more